Yelate

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Yelate

What is Yelate? Foundational Overview

Property Description
Active ingredient Duloxetine hydrochloride
Form Enteric-coated capsules (Delayed-release)
Pharmacological class Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)
Common use Modulates mood and chronic pain signals
Origin Synthetic compound

What Type of Medicine Is Yelate (Duloxetine)?

Yelate is a prescription-only medicine and a synthetic compound that is formally categorized as a Serotonin-Norepinephrine Reuptake Inhibitor (SNRI). This classification designates the medicine as a psychotropic medication and a central nervous system agent. The active ingredient, Duloxetine hydrochloride, is the core substance, distinguished by its recognized ability to inhibit the reuptake of both serotonin and norepinephrine. The compound is characterized by its sustained action in managing neural pathways.

Composition and Pharmaceutical Form

The medicine is supplied for the oral route of administration as a single active ingredient product in the form of specialized enteric-coated capsules, which are designed for delayed-release. This specific pharmaceutical presentation is a differentiating factor, as the enteric coating protects the acid-sensitive Duloxetine from the stomach environment, ensuring the active substance is released in the intestine to achieve a systemic effect. This controlled release mechanism is designed for optimizing the drug’s absorption profile.

General Therapeutic Purpose

The fundamental general purpose of Yelate is derived from its physiological action to enhance monoaminergic neurotransmission. This action is utilized for stabilizing emotional pathways and for influencing the descending pain pathways in the central nervous system. As a result, the drug is designed to help individuals manage conditions that involve both emotional instability and persistent, chronic discomfort, establishing its role as a versatile agent.

What side effects are possible with Yelate?

Possible side effects and safety information

The safety profile of Yelate (duloxetine) is documented through regulatory sources and organized by the likelihood of occurrence and the physiological system affected. Adverse reactions are classified using standard frequency categories derived from clinical trial data, establishing a framework for understanding potential effects.

Very Common adverse reactions, defined as occurring in 1 out of 10 people or more, include nausea, dry mouth, and headache. Common adverse reactions (occurring in 1 to 10 out of 100 people) include dizziness, somnolence (drowsiness), insomnia, constipation, diarrhea, fatigue, and hyperhidrosis (excessive sweating). These effects are formally grouped into System-Organ Classes such as Gastrointestinal Disorders, Nervous System Disorders, and Psychiatric Disorders.


Serious Adverse Reactions and Safety Constraints

The official labeling highlights several serious safety concerns. These include the potential for Serotonin Syndrome, cases of hepatotoxicity (liver injury) that have been reported, and an increased risk of suicidal thoughts and behaviors, particularly in children, adolescents, and young adults. The risk of angle-closure glaucoma is also noted.

Safety restrictions define conditions where the medication should not be used. It is contraindicated in patients receiving Monoamine Oxidase Inhibitors (MAOIs) or those with uncontrolled narrow-angle glaucoma. Furthermore, the medicine is ordinarily not recommended for individuals with severe renal impairment or hepatic failure due to increased safety risks. Certain safety concerns, such as the increased risk of certain symptoms, are more commonly noted early in treatment or following dose adjustments.

Overdose and Emergency Response

Overdose and when to seek help

The information below summarizes the officially documented descriptions of overdose for Yelate (Duloxetine) and regulatory guidance on seeking medical assistance.

Documented Overdose Manifestations

Official labeling states that overdose exposure may lead to signs involving the Central Nervous System, cardiovascular, and autonomic systems, with documented manifestations including:

  • CNS Effects: Somnolence (drowsiness), seizures, syncope (fainting), coma, and unresponsiveness.
  • Cardiovascular Signs: Tachycardia (rapid heart rate) and fluctuations in blood pressure (increased or decreased).
  • Other Symptoms: Vomiting and diarrhea.

Severe and Life-Threatening Outcomes

Regulatory documents explicitly list the potential for severe, life-threatening outcomes, notably Serotonin Syndrome and Neuroleptic Malignant Syndrome (NMS)-like reactions. Fatal outcomes have occurred, particularly in cases where the drug was taken with other substances. Serotonin Syndrome is characterized by signs such as hyperthermia (high body temperature), muscle rigidity, and labile blood pressure.

Emergency Action and Management

No specific antidote is known for Yelate overdose. Management is symptomatic and supportive, meaning treatment focuses on managing the manifestations listed above. Procedures that may be considered by medical professionals to reduce absorption include activated charcoal or gastric lavage.

When to Seek Immediate Medical Help:

Individuals must seek medical advice immediately or call emergency services if an overdose is suspected, or if the person has collapsed, had a seizure, has trouble breathing, or cannot be awakened.

Therapeutic Uses of Yelate

Yelate (Duloxetine) is used to help manage symptoms across two therapeutic domains: chronic emotional distress and persistent pain. It is relevant in conditions characterized by periods of heightened symptoms and is generally applied across domains where additional symptomatic support is needed, helping to ease the overall burden of complex manifestations.


Symptom Management and Therapeutic Focus

The medicine is commonly used to help with conditions that include Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), Diabetic Peripheral Neuropathic Pain (DPNP), and Fibromyalgia. It may assist with managing symptom clusters related to persistent mood and supports general well-being during symptomatic phases.

“The medication is applied in scenarios where symptoms interfere with daily functioning, and may assist with easing the overall symptom load.”

The medication is relevant in clinical settings marked by chronic pain syndromes, used in situations involving certain distressing symptoms such as burning, shooting nerve pain, or widespread body aches. It is applied in addressing groups of symptoms that may become intense, which may assist with easing discomfort and helps patients cope more steadily with symptom fluctuations.

Quick Fact: Contextual Focus
Yelate is commonly used when symptoms involve both emotional distress (like chronic worry) and physical discomfort (like chronic nerve pain), supporting general well-being during symptomatic phases.

Eligibility and Restrictions for Use

Yelate (duloxetine) is a prescription medicine with eligibility determined by strict regulatory guidelines regarding a patient’s medical status, age, and concurrent therapies. Absolute Contraindications mean the medicine must not be used:

  • In patients with known hypersensitivity to the drug.
  • If the patient is taking or has recently stopped taking a Monoamine Oxidase Inhibitor (MAOI).
  • In cases of severe hepatic impairment (liver disease).
  • In cases of severe renal impairment (creatinine clearance < 30 ml/ min) or uncontrolled hypertension.

Age and Reproductive Status

Use in children and adolescents under 18 is generally not recommended for major depressive disorder (MDD) due to efficacy and safety concerns. However, the drug is established for specific conditions, such as Generalized Anxiety Disorder (GAD) in patients ge 7 years.

For pregnancy and breastfeeding, the drug is not generally recommended and should only be used if the potential benefit justifies the potential risk. Caution is specifically advised when treating patients with a history of mania, seizure disorders, or those at risk of narrow-angle glaucoma.

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

This section outlines the officially documented interaction patterns for Yelate (Duloxetine) based on government regulatory information.


Contraindicated Combinations

Certain combinations are formally prohibited due to the risk of severe adverse events:

  • Monoamine Oxidase Inhibitors (MAOIs): Yelate is contraindicated within 14 days of stopping an MAOI, and an MAOI cannot be started within 5 days of stopping Yelate. This includes psychiatric MAOIs, linezolid, and intravenous methylene blue.
  • Potent CYP1A2 Inhibitors: Co-administration with strong inhibitors, such as fluvoxamine, ciprofloxacin, or enoxacin, is prohibited, as this significantly increases Duloxetine concentration.

Pharmacodynamic and Exposure Interactions

Interactions resulting in additive effects or altered drug levels are officially documented:

  • Serotonergic Agents: Combined use with other serotonergic medicines (e.g., triptans, SSRIs) increases the risk of Serotonin Syndrome.
  • CNS Depressants: Co-administration with centrally-acting agents may result in additive CNS depression.
  • Hemostasis-Interfering Drugs: Combining Yelate with agents like NSAIDs or oral anticoagulants is noted to increase the risk of bleeding events.
  • Alcohol and Chronic Liver Disease: Use is avoided in patients with substantial alcohol use or chronic liver disease due to increased risk of liver injury.

Population-Specific Constraints

Regulatory documents advise avoiding Yelate use in cases of severe renal impairment or hepatic impairment due to substantially impaired clearance, which elevates exposure and accumulation risk.

Mechanism of Action

Molecular Action: Inhibiting Neurotransmitter Reuptake

The primary action of Yelate involves a mechanism focused on two specific transporters on presynaptic neurons in the central nervous system: the Serotonin Transporter (SERT) and the Norepinephrine Transporter (NET). The molecule is an inhibitor of both transporters. By binding to and blocking the transporters, Duloxetine prevents the rapid removal of the neurotransmitters serotonin (5-HT) and norepinephrine (NE) from the synaptic cleft. This results in a sustained, elevated concentration of both monoamines, leading to increased and prolonged activation of postsynaptic receptors.


Pathway Modulation: Amplifying Descending Inhibition

The increase in available 5-HT and NE directly strengthens the function of the body's Descending Pain Inhibitory Pathways (DPIC). These signals originate in brainstem nuclei and project down the spinal cord to inhibit the transmission of incoming nociceptive signals in the spinal dorsal horn. This amplification contributes to the modulation of activity within targeted signaling pathways and to the central modulation of nociceptive signaling and affective circuitry activity. This physiological change requires a period of neuronal adaptation—a key mechanistic limitation that delays the full functional effect.

Dosage and Administration Information

How to Use Yelate (Duloxetine) — Administration Guidelines

These instructions outline the procedural steps and dosing regimen for Yelate.

Administration Scope

Feature Official Instruction
Route of Administration Oral (by mouth). Contents of specific delayed-release sprinkle capsules may also be administered via nasogastric tube (NG tube).
Dosing Schedule Taken once daily or twice daily, depending on the prescribed indication and initial regimen. Doses must be taken at approximately the same time(s) every day.
Timing with Meals May be taken with or without food.
Preparation Standard capsules must be swallowed whole. Do not split, crush, or chew the capsules. Specific sprinkle capsules may be opened and the contents sprinkled over applesauce for administration.

Population-Specific Rules

Administration guidelines vary based on age and clinical status:

  • Pediatric Use: Specific starting doses and dose-adjustment schedules are outlined for children (e.g., in Generalized Anxiety Disorder, starting at 30 mg once daily for two weeks).
  • Geriatric Use: An initial lower starting dose may be recommended for older adults before increasing to the target maintenance dose.
  • Physiological Constraints: The medicine's use is contraindicated or must be avoided in patients with severe renal impairment (e.g., GFR < 30 mL/min) and in cases of hepatic impairment (chronic liver disease or cirrhosis).

Procedural and Discontinuation Rules

If a dose is missed, it should be taken as soon as remembered. However, if it is almost time for the next scheduled dose, the missed dose must be skipped, and the patient should resume the regular schedule; do not take two doses to compensate. When discontinuing treatment, the dosage must be gradually reduced (tapered) to minimize potential symptoms.

Recent Clinical Evidence

Yelate: Recent Clinical Evidence

Phase III Clinical Trials: Efficacy and Safety

Research has explored whether this combination of compounds was investigated as a potential option for patients reporting moderate to severe pain in cancer. This research was generally conducted via double-blind, randomized, placebo-controlled trials (RCTs).

  • Primary Efficacy Endpoint: Studies examined the combination's impact on pain-related physiological markers. Research evaluated whether this approach correlated with a change in reported pain scores over time, typically measured by the Numeric Rating Scale (NRS) score at week 4.

  • Study Design and Scope: The combination was studied alongside single-target therapies as controls. Research also focused on the timing of reported changes in pain scores. A post-hoc analysis explored the potential relationship between adherence to the dosage schedule and reported outcomes over 12 weeks.

  • Safety Profile Review: Research into the product’s safety and tolerability profile is ongoing and data remains limited. Adverse events (AEs) documented during the initial trials included reports of mild gastrointestinal upset, dizziness, and fatigue. Trial protocols typically excluded participants with severe hepatic impairment.

Study Limitations and Patient Populations

Trial design introduced specific limitations on the generalizability of the findings. The scope of clinical research was restricted mainly to adult patients (age 18–65) experiencing chronic, non-acute pain that had persisted for at least three months. Studies mainly examined a fixed-dose combination, and evidence is limited on the effects of varying the ratio of the two active ingredients.

Frequently Asked Questions (FAQ)

Common questions about Yelate (FAQ)


Q: How long does it typically take to feel the benefits of Yelate for depression or anxiety?

According to official product information, initial improvements in symptoms such as sleep, energy, or appetite may be noticed within the first one to two weeks of treatment. However, the full therapeutic benefit for depression or anxiety may take longer, often requiring several weeks, potentially six to eight weeks, to be fully observed.


Q: How quickly does Yelate start working for nerve pain?

Studies on the drug’s effectiveness for pain conditions, such as diabetic nerve pain, indicate that patients may begin to experience some improvement in pain symptoms within approximately one to two weeks of consistent use. Patients are instructed to follow their prescribing regimen for optimal results.


Q: Does Yelate cause weight gain or weight loss in most people?

Official information from clinical trials indicates that decreased appetite and weight loss were commonly reported, especially when starting the medication. However, in studies evaluating long-term use, there have been reports of a modest average weight gain among patients.


Q: Is it common to experience increased sweating or dry mouth with Yelate?

Yes, dry mouth is noted in regulatory documents as a very common side effect. Increased sweating, also known as hyperhidrosis, is listed as a common side effect reported by patients in clinical trials.


Q: Does Yelate have a potential for causing liver problems?

The official product labeling indicates that cases of hepatotoxicity, or liver injury, have been reported in patients taking this medicine. For this reason, the drug should not be used in individuals with chronic liver disease or cirrhosis.


Q: Is Yelate known to cause sexual side effects, and are they permanent?

Sexual side effects such as decreased libido (sex drive), difficulty achieving orgasm, and ejaculation failure in men are known to occur during treatment. While these effects usually resolve after stopping the medicine, post-marketing reports for drugs in this class have noted persistent sexual dysfunction after treatment discontinuation.


Q: Can Yelate be taken with or without food?

The administration guidelines in the official product information specify that Yelate may be taken either with food or without it. The importance of consistent administration as part of the regimen is often noted.


Q: Is it necessary to swallow the Yelate capsule whole, or can I open it?

Standard delayed-release capsules must be swallowed whole to protect the medication from stomach acid. They must never be crushed, chewed, or opened. Note that some specific sprinkle capsules may be designed to be opened and mixed with soft foods like applesauce; this difference in administration is due to a distinct pharmaceutical formulation.


Q: What is Yelate different from other common antidepressants (like SSRIs)?

Yelate is classified as a Serotonin-Norepinephrine Reuptake Inhibitor (SNRI) because it works by inhibiting the reuptake of two neurotransmitters: serotonin and norepinephrine. Selective Serotonin Reuptake Inhibitors (SSRIs) primarily target only serotonin.


Q: Does Yelate primarily treat mental health, or is it a pain medication too?

Yelate is officially approved to treat conditions in both areas. Its indications include mental health conditions like Major Depressive Disorder and Generalized Anxiety Disorder, as well as chronic pain conditions like Fibromyalgia and Diabetic Peripheral Neuropathic Pain.


Q: Is it normal to feel worse or have increased anxiety when first starting Yelate?

Regulatory warnings indicate that this medicine may cause changes in mood or behavior, including increased anxiety, agitation, nervousness, or irritability. These effects are possible at any time but are noted to occur more commonly during the beginning of treatment or after a dose change.


Q: Why is Yelate prescribed for chronic musculoskeletal pain?

Yelate is approved to treat chronic pain, including chronic musculoskeletal pain, based on its dual action on neurotransmitters. Its mechanism is believed to strengthen the body's natural descending pain inhibitory pathways in the spinal cord, which helps to block pain signals.


Q: Does Yelate work immediately, or does it build up in the system?

While the drug’s action starts quickly at the molecular level, achieving the full therapeutic effect relies on a period of neuronal adaptation in the central nervous system. This means that consistent, daily use over several weeks is typically necessary for the medicine to reach its full effect.


Q: What should I do if I feel dizzy or lightheaded after taking Yelate?

Dizziness is listed as a common side effect in the official product information. Official safety information advises patients to take care to sit up or stand up slowly, especially when initiating treatment or following a dose increase, to minimize the risk of dizzy or fainting spells.


Q: Why does Yelate sometimes cause low sodium levels (hyponatremia)?

Official labeling notes that low sodium levels, or hyponatremia, may occur with this medication. This is often linked to the Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH), which causes the body to retain excess water, thereby diluting the blood's sodium concentration.


Q: Is it normal to have changes in appetite when starting Yelate?

Yes, regulatory documents indicate that decreased appetite is a commonly reported side effect in patients taking this medication. This change is often most notable when starting treatment.


Q: Does Yelate affect my ability to drive or operate heavy machinery?

Because this medicine may cause drowsiness (somnolence) or dizziness, official warnings advise caution. Regulatory warnings advise that individuals should not drive or operate heavy machinery until they are certain how this medication affects their judgment and physical coordination.


Q: Why is Yelate sometimes used for stress urinary incontinence in women?

In some regions, this medicine is approved for the treatment of moderate to severe stress urinary incontinence (SUI) in women. It is believed to work by strengthening the tone of the urethral sphincter muscles through increased nerve stimulation.


Q: What are the long-term side effects or risks associated with taking Yelate for many years?

Controlled clinical trials have not systematically evaluated the long-term safety of the drug beyond approximately nine weeks for some indications. Therefore, prescribing healthcare providers are typically advised to periodically re-evaluate the drug's long-term usefulness.


Q: Can Yelate cause an increase in manic symptoms for people with bipolar disorder?

Official warnings state there is a risk of activating mania or hypomania in patients, particularly those with Bipolar Disorder. The medicine should therefore be used with caution in individuals who have a history of mania.


Q: How does Yelate's action on nerve signals help with pain?

The medicine increases the amounts of the neurotransmitters serotonin and norepinephrine available in the central nervous system. This action helps to boost the activity of nerves in the Descending Pain Inhibitory Pathways that run down the spinal cord, effectively helping to block pain signals from reaching the brain.


Q: Does the generic version of Yelate work as well as the brand name?

Generic versions of the medicine are approved by regulatory bodies only after demonstrating bioequivalence to the brand-name product. This means the generic must deliver the active ingredient to the bloodstream in the same amount and at the same rate as the original medication.

How should Yelate be stored and disposed of?

How to Store and Dispose of Yelate

Yelate (duloxetine delayed-release capsules) must be stored according to specific regulatory requirements to maintain its integrity and effectiveness.


Storage and Handling

Requirement Description
Temperature Store at Controlled Room Temperature (20^circ to 25 C, or 68^circ to 77 F).
Container Keep in the original container with the cap tightly closed to protect it from moisture.
Handling The capsule must be swallowed whole; do not crush, chew, or open the delayed-release capsule.
Child Safety Keep the medicine out of the sight and reach of children.

Disposal

Unused or expired Yelate must be discarded properly. Do not dispose of the medicine via wastewater or household trash. Dispose of the product through an official drug take-back program or by following local regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Yelate found in:

A-Z Index: